The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc− cystine transporter: a new action for an old drug
Abstract
Although cyst(e)ine is nutritionally a non-essential amino acid, lymphoid cells cannot synthesize it, rendering their growth dependent on uptake of cyst(e)ine from their microenvironment. Accordingly, we previously suggested that the x(c)- plasma membrane cystine transporter provided a target for lymphoid cancer therapy. Its inhibition could lead to cyst(e)ine deficiency in lymphoma cells via reduction of both their cystine uptake and cysteine supply by somatic cells. In this study, using rat Nb2 lymphoma cultures, drugs were screened for growth arrest based on x(c)- inhibition. Sulfasalazine was fortuitously found to be a novel, potent inhibitor of the x(c)- transporter. It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of x(c)--mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid. Sulfasalazine was even more effective against human non-Hodgkin's lymphoma (DoHH2) cultures. In rats (n = 13), sulfasalazine (i.p.) markedly inhibited growth of well-developed, rapidly growing rat Nb2 lymphoma transplants without apparent side-effects. Reduced, macrophage-mediated supply of cysteine was probably involved. In five rats, 90-100% tumor growth suppression, relative to controls, was obtained. The x(c)- cystine transporter represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular cyst(e)ine.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DLBCLs with low system xc− activity are more susceptible to ferroptosis”
From Ferroptosis: Death by Lipid Peroxidation (2016) · cites this paper as [77]
In the citing paper
“sulfasalazine potently inhibited the growth of lymphomas with low-level expression of SLC7A11, a subunit of system xc− [77, 78].”
From Ferroptosis: Death by Lipid Peroxidation (2016) · cites this paper as [77]
In the citing paper
“Since some leukemias and lymphomas have a defective transsulfuration pathway [76, 77]”
From Ferroptosis: Death by Lipid Peroxidation (2016) · cites this paper as [77]
Citations
Cites
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Hastings, R. C. (1996) · JAMA · doi:10.1001/jama.1996.03540120077042 · Cited by 2,375
Determination of subcutaneous tumor size in athymic (nude) mice
Tomayko, M. M., & Reynolds, C. P. (1989) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00300234 · Cited by 1,830
Cancer: Principles and Practice of Oncology
Gunn, W. G. (1994) · JAMA · doi:10.1001/jama.1994.03510350091047 · Cited by 1,803
Inhibition of NF-κB by Sodium Salicylate and Aspirin
Kopp, E. B., & Ghosh, S. (1994) · Science · doi:10.1126/science.8052854 · Cited by 1,744
Sato, H., Tamba, M., Ishii, T., & Bannai, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11455 · Cited by 1,111
Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B
Wahl, C., Liptay, S., Adler, G., & Schmid, R. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci992 · Cited by 742
Wang, C.-Y., Guttridge, D. C., Mayo, M. W., & Baldwin, A. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.5923 · Cited by 594
Back, S. A., Gan, X., Li, Y., Rosenberg, P. A., & Volpe, J. J. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-16-06241.1998 · Cited by 586
Exchange of cystine and glutamate across plasma membrane of human fibroblasts.
Bannai, S. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35926-4 · Cited by 549
Analgesic-Antipyretic and Antiinflammatory Agents and Drugs Employed in the Treatment of Gout
Insel, P. (1996) · Medical Entomology and Zoology · Cited by 416
Cited by
Sorted by citations
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691
Ferroptosis: process and function
Xie, Y., Hou, W., Song, X., Yu, Y., Huang, J., Sun, X., Kang, R., & Tang, D. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.158 · Cited by 3,727
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
Ferroptosis: Death by Lipid Peroxidation
Yang, W. S., & Stockwell, B. R. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.10.014 · Cited by 3,088
Broadening horizons: the role of ferroptosis in cancer
Chen, X., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00462-0 · Cited by 3,012
Metadata
- Authors
- Gout, P., Buckley, A., Simms, C., & Bruchovsky, N.
- Affiliations
- BC Cancer Agency (CA)
- University of Cincinnati Medical Center (US)
- Venue
- Leukemia
- Published
- 2001-10-01
- Volume
- 15
- Issue
- 10
- Pages
- 1633-1640
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2137749199
- Cited by
- 640
- References
- 41
- Citations by year
- 2026: 32 · 2025: 47 · 2024: 62 · 2023: 63 · 2022: 74 · 2021: 93 · 2020: 46 · 2019: 41 · 2018: 23 · 2017: 28 · 2016: 23 · 2015: 22 · 2014: 14 · 2013: 10 · 2012: 18
- FWCI
- 0.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ohio Cancer Research Associates
- National Institutes of Health (5r01dk053452-05)
- BC Cancer Agency
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 53452)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Sulfur Compounds in Biology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- sulfasalazine, cystine uptake, lymphoma, cysteine deficiency, non-Hodgkin lymphoma, sulfapyridine, 5-aminosalicylic acid, tumor growth inhibition, drug repurposing
- MeSH terms
- Animals, Anti-Inflammatory Agents, Non-Steroidal, Antineoplastic Agents, Carrier Proteins, Cell Division, Drug Evaluation, Preclinical, Humans, Injections, Intraperitoneal, Lymphoma, Neoplasm Transplantation, Rats, Inbred Strains, Sulfasalazine, Tumor Cells, Cultured, Inhibitory Concentration 50, Amino Acid Transport System y+, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
